nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—MAP2K1—embryo—polycystic ovary syndrome	0.0199	0.115	CbGeAlD
Trametinib—MAP2K1—adipose tissue—polycystic ovary syndrome	0.0131	0.0761	CbGeAlD
Trametinib—MAP2K2—endometrium—polycystic ovary syndrome	0.0128	0.0743	CbGeAlD
Trametinib—CYP3A4—urine—polycystic ovary syndrome	0.0127	0.0737	CbGeAlD
Trametinib—MAP2K2—uterus—polycystic ovary syndrome	0.0118	0.0685	CbGeAlD
Trametinib—MAP2K1—adrenal gland—polycystic ovary syndrome	0.0118	0.0682	CbGeAlD
Trametinib—MAP2K2—pituitary gland—polycystic ovary syndrome	0.0116	0.0673	CbGeAlD
Trametinib—MAP2K2—adipose tissue—polycystic ovary syndrome	0.0115	0.067	CbGeAlD
Trametinib—MAP2K1—female gonad—polycystic ovary syndrome	0.011	0.0636	CbGeAlD
Trametinib—MAP2K2—adrenal gland—polycystic ovary syndrome	0.0104	0.0601	CbGeAlD
Trametinib—MAP2K1—endocrine gland—polycystic ovary syndrome	0.0102	0.0592	CbGeAlD
Trametinib—MAP2K2—female gonad—polycystic ovary syndrome	0.00965	0.056	CbGeAlD
Trametinib—MAP2K2—endocrine gland—polycystic ovary syndrome	0.00898	0.0521	CbGeAlD
Trametinib—CYP2C8—endometrium—polycystic ovary syndrome	0.00443	0.0257	CbGeAlD
Trametinib—CYP2C8—pituitary gland—polycystic ovary syndrome	0.00401	0.0233	CbGeAlD
Trametinib—CYP2C8—vagina—polycystic ovary syndrome	0.00332	0.0193	CbGeAlD
Trametinib—CYP2C8—endocrine gland—polycystic ovary syndrome	0.00311	0.018	CbGeAlD
Trametinib—Pain in extremity—Metformin—polycystic ovary syndrome	0.00266	0.0395	CcSEcCtD
Trametinib—Dehydration—Metformin—polycystic ovary syndrome	0.00248	0.0368	CcSEcCtD
Trametinib—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.00243	0.0361	CcSEcCtD
Trametinib—Pancreatitis—Metformin—polycystic ovary syndrome	0.00226	0.0335	CcSEcCtD
Trametinib—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.00221	0.0328	CcSEcCtD
Trametinib—Neutropenia—Metformin—polycystic ovary syndrome	0.00215	0.0319	CcSEcCtD
Trametinib—CYP3A4—endocrine gland—polycystic ovary syndrome	0.00211	0.0122	CbGeAlD
Trametinib—Infestation NOS—Metformin—polycystic ovary syndrome	0.00205	0.0305	CcSEcCtD
Trametinib—Infestation—Metformin—polycystic ovary syndrome	0.00205	0.0305	CcSEcCtD
Trametinib—Bradycardia—Metformin—polycystic ovary syndrome	0.00187	0.0278	CcSEcCtD
Trametinib—Oedema peripheral—Metformin—polycystic ovary syndrome	0.00181	0.0269	CcSEcCtD
Trametinib—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00181	0.0269	CcSEcCtD
Trametinib—Eye disorder—Metformin—polycystic ovary syndrome	0.00172	0.0256	CcSEcCtD
Trametinib—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00171	0.0254	CcSEcCtD
Trametinib—Angiopathy—Metformin—polycystic ovary syndrome	0.00167	0.0248	CcSEcCtD
Trametinib—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00166	0.0246	CcSEcCtD
Trametinib—Chills—Metformin—polycystic ovary syndrome	0.00165	0.0245	CcSEcCtD
Trametinib—Malnutrition—Metformin—polycystic ovary syndrome	0.0016	0.0238	CcSEcCtD
Trametinib—Erythema—Metformin—polycystic ovary syndrome	0.0016	0.0238	CcSEcCtD
Trametinib—Dysgeusia—Metformin—polycystic ovary syndrome	0.00157	0.0233	CcSEcCtD
Trametinib—Muscle spasms—Metformin—polycystic ovary syndrome	0.00154	0.0229	CcSEcCtD
Trametinib—Vision blurred—Metformin—polycystic ovary syndrome	0.00151	0.0224	CcSEcCtD
Trametinib—Hypertension—Metformin—polycystic ovary syndrome	0.00138	0.0206	CcSEcCtD
Trametinib—Myalgia—Metformin—polycystic ovary syndrome	0.00136	0.0203	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00136	0.0201	CcSEcCtD
Trametinib—Oedema—Metformin—polycystic ovary syndrome	0.00131	0.0194	CcSEcCtD
Trametinib—Infection—Metformin—polycystic ovary syndrome	0.0013	0.0193	CcSEcCtD
Trametinib—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00128	0.0191	CcSEcCtD
Trametinib—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.00128	0.019	CcSEcCtD
Trametinib—Skin disorder—Metformin—polycystic ovary syndrome	0.00127	0.0189	CcSEcCtD
Trametinib—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.00126	0.0188	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.00119	0.0177	CcSEcCtD
Trametinib—Decreased appetite—Metformin—polycystic ovary syndrome	0.00114	0.0169	CcSEcCtD
Trametinib—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.00113	0.0168	CcSEcCtD
Trametinib—Fatigue—Metformin—polycystic ovary syndrome	0.00113	0.0167	CcSEcCtD
Trametinib—Constipation—Metformin—polycystic ovary syndrome	0.00112	0.0166	CcSEcCtD
Trametinib—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00107	0.0159	CcSEcCtD
Trametinib—Abdominal pain—Metformin—polycystic ovary syndrome	0.00103	0.0154	CcSEcCtD
Trametinib—Asthenia—Metformin—polycystic ovary syndrome	0.000939	0.0139	CcSEcCtD
Trametinib—Pruritus—Metformin—polycystic ovary syndrome	0.000926	0.0137	CcSEcCtD
Trametinib—Diarrhoea—Metformin—polycystic ovary syndrome	0.000895	0.0133	CcSEcCtD
Trametinib—Dizziness—Metformin—polycystic ovary syndrome	0.000865	0.0128	CcSEcCtD
Trametinib—Vomiting—Metformin—polycystic ovary syndrome	0.000832	0.0124	CcSEcCtD
Trametinib—Rash—Metformin—polycystic ovary syndrome	0.000825	0.0122	CcSEcCtD
Trametinib—Dermatitis—Metformin—polycystic ovary syndrome	0.000824	0.0122	CcSEcCtD
Trametinib—Headache—Metformin—polycystic ovary syndrome	0.00082	0.0122	CcSEcCtD
Trametinib—Nausea—Metformin—polycystic ovary syndrome	0.000777	0.0115	CcSEcCtD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	0.000135	0.000177	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FST—polycystic ovary syndrome	0.000134	0.000177	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TNRC6B—polycystic ovary syndrome	0.000134	0.000176	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—IL6—polycystic ovary syndrome	0.000134	0.000176	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—INS—polycystic ovary syndrome	0.000134	0.000176	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—IL6—polycystic ovary syndrome	0.000133	0.000175	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—IL6—polycystic ovary syndrome	0.000133	0.000175	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—IL6—polycystic ovary syndrome	0.000133	0.000175	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—IL6—polycystic ovary syndrome	0.000133	0.000175	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—IL6—polycystic ovary syndrome	0.000133	0.000174	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000133	0.000174	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000132	0.000174	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—IRS2—polycystic ovary syndrome	0.000132	0.000174	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CRP—polycystic ovary syndrome	0.000132	0.000174	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—IL6—polycystic ovary syndrome	0.000132	0.000174	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—IL6—polycystic ovary syndrome	0.000132	0.000173	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—CYP19A1—polycystic ovary syndrome	0.000131	0.000173	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—LHB—polycystic ovary syndrome	0.000131	0.000172	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—IL6—polycystic ovary syndrome	0.00013	0.000171	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—IL6—polycystic ovary syndrome	0.00013	0.000171	CbGpPWpGaD
Trametinib—CYP3A4—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	0.00013	0.00017	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—AKT2—polycystic ovary syndrome	0.000129	0.00017	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000129	0.000169	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000128	0.000168	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	0.000128	0.000168	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ATF1—polycystic ovary syndrome	0.000128	0.000168	CbGpPWpGaD
Trametinib—MAP2K1—Disease—AKR1C3—polycystic ovary syndrome	0.000128	0.000168	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—PPARG—polycystic ovary syndrome	0.000127	0.000168	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FST—polycystic ovary syndrome	0.000126	0.000165	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TNRC6B—polycystic ovary syndrome	0.000126	0.000165	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AKR1C2—polycystic ovary syndrome	0.000126	0.000165	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—TEAD2—polycystic ovary syndrome	0.000126	0.000165	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—INS—polycystic ovary syndrome	0.000125	0.000164	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—IL6—polycystic ovary syndrome	0.000124	0.000163	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—IL6—polycystic ovary syndrome	0.000124	0.000163	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—IL6—polycystic ovary syndrome	0.000124	0.000163	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000124	0.000163	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000124	0.000163	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—IRS1—polycystic ovary syndrome	0.000123	0.000162	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—IL6—polycystic ovary syndrome	0.000123	0.000162	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SCT—polycystic ovary syndrome	0.000123	0.000161	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—LHB—polycystic ovary syndrome	0.000123	0.000161	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—IL6—polycystic ovary syndrome	0.000122	0.00016	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—IL6—polycystic ovary syndrome	0.000121	0.00016	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000121	0.000159	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—AKT2—polycystic ovary syndrome	0.000121	0.000159	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	0.000121	0.000159	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.00012	0.000158	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ATF1—polycystic ovary syndrome	0.000119	0.000157	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	0.000119	0.000156	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—VEGFA—polycystic ovary syndrome	0.000118	0.000156	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—TAB1—polycystic ovary syndrome	0.000118	0.000155	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—IL6—polycystic ovary syndrome	0.000118	0.000155	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000117	0.000154	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PRL—polycystic ovary syndrome	0.000117	0.000153	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000116	0.000153	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—IRS1—polycystic ovary syndrome	0.000115	0.000152	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000115	0.000151	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TCF7L2—polycystic ovary syndrome	0.000115	0.000151	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SCT—polycystic ovary syndrome	0.000115	0.000151	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000114	0.00015	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—AKT2—polycystic ovary syndrome	0.000114	0.00015	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	0.000114	0.000149	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000113	0.000149	CbGpPWpGaD
Trametinib—MAP2K2—Disease—SLC2A4—polycystic ovary syndrome	0.000113	0.000149	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000112	0.000148	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—VEGFA—polycystic ovary syndrome	0.000111	0.000146	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—TAB1—polycystic ovary syndrome	0.00011	0.000145	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—IL6—polycystic ovary syndrome	0.00011	0.000145	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.00011	0.000144	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PRL—polycystic ovary syndrome	0.000109	0.000144	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PRL—polycystic ovary syndrome	0.000108	0.000142	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000108	0.000142	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TCF7L2—polycystic ovary syndrome	0.000107	0.000141	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000107	0.00014	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—AKT2—polycystic ovary syndrome	0.000107	0.00014	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000107	0.00014	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	0.000106	0.00014	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—CYP1A1—polycystic ovary syndrome	0.000106	0.000139	CbGpPWpGaD
Trametinib—MAP2K1—Disease—SLC2A4—polycystic ovary syndrome	0.000106	0.000139	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PNPLA2—polycystic ovary syndrome	0.000105	0.000138	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000105	0.000138	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000105	0.000138	CbGpPWpGaD
Trametinib—CYP3A4—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	0.000104	0.000137	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PRL—polycystic ovary syndrome	0.000101	0.000133	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—INSR—polycystic ovary syndrome	0.0001	0.000132	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SRD5A1—polycystic ovary syndrome	9.97e-05	0.000131	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—YAP1—polycystic ovary syndrome	9.97e-05	0.000131	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—BCL2—polycystic ovary syndrome	9.97e-05	0.000131	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—GAB1—polycystic ovary syndrome	9.83e-05	0.000129	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL18—polycystic ovary syndrome	9.82e-05	0.000129	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—NRG1—polycystic ovary syndrome	9.6e-05	0.000126	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	9.55e-05	0.000126	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—STAR—polycystic ovary syndrome	9.51e-05	0.000125	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	9.4e-05	0.000124	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—INSR—polycystic ovary syndrome	9.4e-05	0.000124	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	9.4e-05	0.000124	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—BCL2—polycystic ovary syndrome	9.32e-05	0.000123	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NMNAT3—polycystic ovary syndrome	9.32e-05	0.000123	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PGR—polycystic ovary syndrome	9.3e-05	0.000122	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—IL6—polycystic ovary syndrome	9.2e-05	0.000121	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL18—polycystic ovary syndrome	9.19e-05	0.000121	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—IL6—polycystic ovary syndrome	9.04e-05	0.000119	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NCOR1—polycystic ovary syndrome	9.03e-05	0.000119	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—NRG1—polycystic ovary syndrome	8.98e-05	0.000118	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	8.93e-05	0.000117	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NRG1—polycystic ovary syndrome	8.86e-05	0.000117	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	8.79e-05	0.000116	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PGR—polycystic ovary syndrome	8.7e-05	0.000114	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—GHRL—polycystic ovary syndrome	8.65e-05	0.000114	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PLAT—polycystic ovary syndrome	8.65e-05	0.000114	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—IL6—polycystic ovary syndrome	8.6e-05	0.000113	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—LPCAT2—polycystic ovary syndrome	8.52e-05	0.000112	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SUOX—polycystic ovary syndrome	8.52e-05	0.000112	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—HMMR—polycystic ovary syndrome	8.48e-05	0.000112	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—IL6—polycystic ovary syndrome	8.46e-05	0.000111	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NCOR1—polycystic ovary syndrome	8.45e-05	0.000111	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—VEGFA—polycystic ovary syndrome	8.44e-05	0.000111	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NRG1—polycystic ovary syndrome	8.29e-05	0.000109	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ATF1—polycystic ovary syndrome	8.25e-05	0.000109	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IRS2—polycystic ovary syndrome	8.22e-05	0.000108	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CRP—polycystic ovary syndrome	8.22e-05	0.000108	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—IL6—polycystic ovary syndrome	8.18e-05	0.000108	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—GHRL—polycystic ovary syndrome	8.09e-05	0.000106	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PLAT—polycystic ovary syndrome	8.09e-05	0.000106	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—HSD3B1—polycystic ovary syndrome	8.09e-05	0.000106	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	8.05e-05	0.000106	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	7.99e-05	0.000105	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MTHFR—polycystic ovary syndrome	7.98e-05	0.000105	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ISYNA1—polycystic ovary syndrome	7.92e-05	0.000104	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—VEGFA—polycystic ovary syndrome	7.9e-05	0.000104	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—POMC—polycystic ovary syndrome	7.9e-05	0.000104	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ATF1—polycystic ovary syndrome	7.72e-05	0.000102	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CRP—polycystic ovary syndrome	7.69e-05	0.000101	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IRS2—polycystic ovary syndrome	7.69e-05	0.000101	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—IL6—polycystic ovary syndrome	7.66e-05	0.000101	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NGFR—polycystic ovary syndrome	7.61e-05	0.0001	CbGpPWpGaD
Trametinib—MAP2K2—Disease—IRS2—polycystic ovary syndrome	7.59e-05	9.98e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	7.58e-05	9.97e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—POMC—polycystic ovary syndrome	7.57e-05	9.95e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PRL—polycystic ovary syndrome	7.55e-05	9.92e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	7.53e-05	9.9e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MTHFR—polycystic ovary syndrome	7.47e-05	9.82e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—LHB—polycystic ovary syndrome	7.38e-05	9.7e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—AKT2—polycystic ovary syndrome	7.27e-05	9.56e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—HSD3B2—polycystic ovary syndrome	7.21e-05	9.48e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IRS1—polycystic ovary syndrome	7.18e-05	9.44e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ADRB2—polycystic ovary syndrome	7.16e-05	9.41e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NGFR—polycystic ovary syndrome	7.12e-05	9.37e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—IRS2—polycystic ovary syndrome	7.1e-05	9.34e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—POMC—polycystic ovary syndrome	7.08e-05	9.31e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PRL—polycystic ovary syndrome	7.06e-05	9.28e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AKR1C1—polycystic ovary syndrome	6.98e-05	9.18e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—AKT2—polycystic ovary syndrome	6.8e-05	8.95e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TEAD2—polycystic ovary syndrome	6.74e-05	8.86e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKR1C2—polycystic ovary syndrome	6.74e-05	8.86e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IRS1—polycystic ovary syndrome	6.72e-05	8.83e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ADRB2—polycystic ovary syndrome	6.7e-05	8.81e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—AKT2—polycystic ovary syndrome	6.64e-05	8.74e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—GNAS—polycystic ovary syndrome	6.64e-05	8.73e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—IRS1—polycystic ovary syndrome	6.63e-05	8.72e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SULT2A1—polycystic ovary syndrome	6.43e-05	8.45e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—INS—polycystic ovary syndrome	6.35e-05	8.35e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NCOR1—polycystic ovary syndrome	6.32e-05	8.32e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—RRM2—polycystic ovary syndrome	6.22e-05	8.18e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—AKT2—polycystic ovary syndrome	6.22e-05	8.18e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—GNAS—polycystic ovary syndrome	6.21e-05	8.17e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NRG1—polycystic ovary syndrome	6.21e-05	8.16e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—IRS1—polycystic ovary syndrome	6.2e-05	8.16e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—AKT2—polycystic ovary syndrome	6.13e-05	8.07e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—YAP1—polycystic ovary syndrome	6e-05	7.89e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—INS—polycystic ovary syndrome	5.94e-05	7.81e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NCOR1—polycystic ovary syndrome	5.92e-05	7.78e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—IL6—polycystic ovary syndrome	5.84e-05	7.68e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—SERPINE1—polycystic ovary syndrome	5.83e-05	7.67e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NRG1—polycystic ovary syndrome	5.81e-05	7.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—BCL2—polycystic ovary syndrome	5.8e-05	7.63e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NAMPT—polycystic ovary syndrome	5.76e-05	7.58e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—AKT2—polycystic ovary syndrome	5.74e-05	7.55e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	5.73e-05	7.54e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP11A1—polycystic ovary syndrome	5.69e-05	7.49e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	5.65e-05	7.43e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	5.65e-05	7.42e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—IL6—polycystic ovary syndrome	5.46e-05	7.19e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—SERPINE1—polycystic ovary syndrome	5.45e-05	7.17e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—BCL2—polycystic ovary syndrome	5.43e-05	7.14e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AKR1C3—polycystic ovary syndrome	5.37e-05	7.07e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	5.35e-05	7.04e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IRS2—polycystic ovary syndrome	5.32e-05	6.99e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP17A1—polycystic ovary syndrome	5.29e-05	6.96e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—LEP—polycystic ovary syndrome	5.2e-05	6.84e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—IL6—polycystic ovary syndrome	5.16e-05	6.78e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	5.11e-05	6.71e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IRS2—polycystic ovary syndrome	4.97e-05	6.54e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—LEP—polycystic ovary syndrome	4.87e-05	6.4e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—IL6—polycystic ovary syndrome	4.83e-05	6.35e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IRS1—polycystic ovary syndrome	4.64e-05	6.1e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—TH—polycystic ovary syndrome	4.58e-05	6.02e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	4.55e-05	5.98e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—POMC—polycystic ovary syndrome	4.47e-05	5.88e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SLC2A4—polycystic ovary syndrome	4.45e-05	5.86e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—INS—polycystic ovary syndrome	4.44e-05	5.85e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IRS1—polycystic ovary syndrome	4.34e-05	5.71e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	4.34e-05	5.71e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IGF1—polycystic ovary syndrome	4.3e-05	5.65e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKT2—polycystic ovary syndrome	4.3e-05	5.65e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP19A1—polycystic ovary syndrome	4.19e-05	5.51e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—POMC—polycystic ovary syndrome	4.18e-05	5.5e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—INS—polycystic ovary syndrome	4.16e-05	5.47e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.08e-05	5.37e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IGF1—polycystic ovary syndrome	4.02e-05	5.29e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKT2—polycystic ovary syndrome	4.02e-05	5.29e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	3.96e-05	5.21e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	3.87e-05	5.09e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.82e-05	5.02e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	3.75e-05	4.93e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GNAS—polycystic ovary syndrome	3.74e-05	4.92e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NCOR1—polycystic ovary syndrome	3.56e-05	4.68e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	3.45e-05	4.54e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP1A1—polycystic ovary syndrome	3.38e-05	4.44e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	3.34e-05	4.39e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL6—polycystic ovary syndrome	3.29e-05	4.32e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	3.22e-05	4.23e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—MTHFR—polycystic ovary syndrome	3.15e-05	4.14e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	3.09e-05	4.07e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL6—polycystic ovary syndrome	3.08e-05	4.05e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	3.05e-05	4.02e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL6—polycystic ovary syndrome	3e-05	3.95e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	2.88e-05	3.79e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	2.84e-05	3.74e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL6—polycystic ovary syndrome	2.81e-05	3.7e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.81e-05	3.69e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—IL6—polycystic ovary syndrome	2.77e-05	3.65e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.63e-05	3.46e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—IL6—polycystic ovary syndrome	2.59e-05	3.41e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PPARG—polycystic ovary syndrome	2.55e-05	3.36e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—POMC—polycystic ovary syndrome	2.52e-05	3.31e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—INS—polycystic ovary syndrome	2.5e-05	3.29e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TH—polycystic ovary syndrome	2.46e-05	3.23e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	2.39e-05	3.14e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	2.25e-05	2.96e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	2.01e-05	2.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL6—polycystic ovary syndrome	1.94e-05	2.55e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	1.91e-05	2.51e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL6—polycystic ovary syndrome	1.82e-05	2.39e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	1.81e-05	2.38e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	1.69e-05	2.22e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	1.37e-05	1.8e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	1.35e-05	1.78e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—INS—polycystic ovary syndrome	1.34e-05	1.77e-05	CbGpPWpGaD
